Triple Negative Breast Cancer Treatment: Use of Platinum and Platinum Analogs

Autor:	Lorenzo Gianni, Claudio Ridolfi, Alessandra Affatato, Eleonora Barzotti, Fabrizio Drudi, Carlotta Santelmo, Alberto Ravaioli, Valentina Arcangeli, Manuela Fantini
Rok vydání:	2012
Předmět:	Oncology Chemotherapy medicine.medical_specialty business.industry medicine.medical_treatment Lipoplatin Cancer Disease medicine.disease Targeted therapy Breast cancer Internal medicine medicine business Triple-negative breast cancer Neoadjuvant therapy
Zdroj:	Journal of Cancer Therapy. :777-781
ISSN:	2151-1942 2151-1934
DOI:	10.4236/jct.2012.325097
Popis:	Triple negative breast cancer (TNBC) is characterized by a high sensitivity to antiblastic drugs and a high pathological complete remission rate after neoadjuvant therapy. In patients showing complete remission, the probability of developing metastatic disease would seem to be reduced. Nonetheless, this cancer has a high percentage of relapse. Anthracyclines, taxanes and platinum compounds are the most effective drugs for the treatment of TNBC. There is substantial evidence to support the efficacy of platinum-based chemotherapy, probably attributable to the mechanism of action of such drugs, which react with the DNA repair system. PARP inhibitors would also seem to be very interesting. Despite promising results, TNBC remains a disease with a poor prognosis due to the lack of targeted therapy. The discovery of new targets and new agents is thus a high priority issue for this type of breast cancer. In this respect, lipoplatin has been identified as a potentially interesting treatment option to evaluate in both neoadjuvant and advanced settings.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::c218dfd357b657592229c90ea0ee435c https://doi.org/10.4236/jct.2012.325097 Zobrazit plný text záznamu